| Effectiveness of the BNT162b2 Covid-19 Vaccine against the B. 1.1. 7 and B. 1.351 Variants LJ Abu-Raddad, H Chemaitelly, ... New England Journal of Medicine, 2021 | 1121 | 2021 |
| Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar H Chemaitelly, P Tang, MR Hasan, S AlMukdad, HM Yassine, ... New England Journal of Medicine 385 (24), e83, 2021 | 912 | 2021 |
| Effects of previous infection and vaccination on symptomatic omicron infections HN Altarawneh, H Chemaitelly, HH Ayoub, P Tang, MR Hasan, ... New England Journal of Medicine 387 (1), 21-34, 2022 | 510 | 2022 |
| BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar P Tang, MR Hasan, H Chemaitelly, HM Yassine, FM Benslimane, ... Nature medicine 27 (12), 2136-2143, 2021 | 478 | 2021 |
| Protection against the Omicron variant from previous SARS-CoV-2 infection HN Altarawneh, H Chemaitelly, MR Hasan, HH Ayoub, S Qassim, ... New England Journal of Medicine 386 (13), 1288-1290, 2022 | 436 | 2022 |
| mRNA-1273 COVID-19 vaccine effectiveness against the B. 1.1. 7 and B. 1.351 variants and severe COVID-19 disease in Qatar H Chemaitelly, HM Yassine, FM Benslimane, HA Al Khatib, P Tang, ... Nature medicine 27 (9), 1614-1621, 2021 | 421 | 2021 |
| Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar LJ Abu-Raddad, H Chemaitelly, HH Ayoub, S AlMukdad, HM Yassine, ... New England Journal of Medicine 386 (19), 1804-1816, 2022 | 396 | 2022 |
| Assessment of the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection in an intense reexposure setting LJ Abu-Raddad, H Chemaitelly, JA Malek, AA Ahmed, YA Mohamoud, ... Clinical Infectious Diseases 73 (7), e1830-e1840, 2021 | 244 | 2021 |
| Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA. 1 and BA. 2 subvariants in Qatar H Chemaitelly, HH Ayoub, S AlMukdad, P Coyle, P Tang, HM Yassine, ... Nature communications 13 (1), 3082, 2022 | 240 | 2022 |
| SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy LJ Abu-Raddad, H Chemaitelly, P Coyle, JA Malek, AA Ahmed, ... EClinicalMedicine 35, 2021 | 190 | 2021 |
| Severity of SARS-CoV-2 reinfections as compared with primary infections LJ Abu-Raddad, H Chemaitelly, R Bertollini, ... New England Journal of Medicine 385 (26), 2487-2489, 2021 | 189 | 2021 |
| Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar LJ Abu-Raddad, H Chemaitelly, HH Ayoub, HM Yassine, FM Benslimane, ... Jama 326 (19), 1930-1939, 2021 | 165 | 2021 |
| Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic LJ Abu-Raddad, H Chemaitelly, HH Ayoub, Z Al Kanaani, A Al Khal, ... Scientific reports 11 (1), 6233, 2021 | 146 | 2021 |
| Characterizing the transitioning epidemiology of herpes simplex virus type 1 in the USA: model-based predictions HH Ayoub, H Chemaitelly, LJ Abu-Raddad BMC medicine 17, 1-12, 2019 | 123 | 2019 |
| Protective effect of previous SARS-CoV-2 infection against Omicron BA. 4 and BA. 5 subvariants HN Altarawneh, H Chemaitelly, HH Ayoub, MR Hasan, P Coyle, ... New England Journal of Medicine 387 (17), 1620-1622, 2022 | 122 | 2022 |
| Epidemiological impact of SARS-CoV-2 vaccination: mathematical modeling analyses M Makhoul, HH Ayoub, H Chemaitelly, S Seedat, GR Mumtaz, S Al-Omari, ... Vaccines 8 (4), 668, 2020 | 110 | 2020 |
| Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar LJ Abu-Raddad, H Chemaitelly, R Bertollini, ... New England Journal of Medicine, 2022 | 99 | 2022 |
| Duration of immune protection of SARS-CoV-2 natural infection against reinfection H Chemaitelly, N Nagelkerke, HH Ayoub, P Coyle, P Tang, HM Yassine, ... Journal of Travel Medicine 29 (8), taac109, 2022 | 97 | 2022 |
| Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses LJ Abu-Raddad, H Chemaitelly, HM Yassine, FM Benslimane, ... Journal of travel medicine 28 (7), taab083, 2021 | 90 | 2021 |
| Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant H Chemaitelly, R Bertollini, LJ Abu-Raddad, ... New England Journal of Medicine 385 (27), 2585-2586, 2021 | 86 | 2021 |
Laith J. Abu-RaddadProfessor of Healthcare Policy and Research, Weill Cornell Medical College – QatarVerified email at qatar-med.cornell.edu
